• anti-beta 2-glycoprotein I antibodies
• antiphospholipid antibodies
• arthralgia
• arthritis

• Male
• Female
• Humans
• Adult
• Middle Aged
• Antiphospholipid Syndrome
• Antibodies, Antiphospholipid
• Antibodies, Anticardiolipin
• Autoantibodies
• beta 2-Glycoprotein I
• Arthritis/epidemiology
• Immunoglobulin A
• Arthralgia

To determine the frequency of serological markers of RA in patients with anti‐β2 glycoprotein I antibodies (aβ2GPI) of IgA isotype.

A retrospective study was conducted on 67 patients with aβ2GPI‐IgA. Ninety healthy blood donors (HBD) were used as a control group. IgG anti‐cyclic citrullinated peptides antibodies (CCP‐Ab) and rheumatoid factors (RF) IgG, IgA, and IgM were detected by enzyme‐linked immunosorbent assay (ELISA).

Seventeen patients and eight HBD had CCP‐Ab and/or RF (25.4% vs. 8.9%, p = 0.005, CI 95% [14.95; 35.79], odds ratio = 3.5). The frequency of CCP‐Ab was significantly higher in patients than in healthy subjects (14.9% vs. 3.3%, p = 0.009). IgA isotype of RF was significantly higher in patients than in controls (7.5% vs. 0%, p = 0.02). In male patients, CCP‐Ab and/or RF were more frequent than in healthy male subjects (37.5% vs. 11.8%, p = 0.02). In patients, no correlation was found between the levels of aβ2GPI‐IgA and CCP‐Ab (r = 0.082, p = 0.51). There was no correlation between the level aβ2GPI‐IgA and the level of the isotypes of RF (IgG, IgA, and IgM) in patients (r = 0.1, p = 0.37; r = 0.17, p = 0.17 and r = 0.07, p = 0.59 respectively).

Frequencies of CCP‐Ab and RF are high in patients with aβ2GPI‐IgA suggesting that these patients are susceptible to developing RA.

• anti-cyclic citrullinated peptides antibodies
• anti-β2 glycoprotein I antibodies
• antiphospholipid syndrome
• rheumatoid arthritis
• rheumatoid factors

The specific value of IgA Anti-β2glycoprotein I antibodies (aB2GP1) in the diagnosis and management of antiphospholipid syndrome (APS) is still controversial and a matter of active debate. The relevance of the IgA aB2GP1 isotype in the pathophysiology of APS has been increasingly studied in the last years. There is well know that subjects with multiple positive APS tests are at increased risk of thrombosis and/or miscarriage. However, these antibodies are not included in the 2006 APS classification criteria. Since 2010 the task force of the Galveston International Congress on APS recommends testing IgA aB2GP1 isotype in patients with APS clinical criteria in the absence of criteria antibodies. In this review, we summarize the molecular and clinical “state of the art” of the IgA aB2GP in the context of APS. We also discuss some of the characteristics that may help to evaluate the real value of the IgA aB2GP1 determination in basic research and clinical practice. The scientific community should be aware of the importance of clarifying the role of IgA aB2GP1 in the APS diagnosis.

• antiphospholipid antibodies
• antiphospholipid syndrome
• domain of Beta 2 Glycoprotein I antibodies
• immunology
• non-criteria
• recurrent pregnancy loss
• stroke
• thrombosis

The aim of this study was to determine the frequency of anti‐cardiolipin antibodies (aCL) and anti‐β2 glycoprotein I antibodies (aβ2GPI) among Tunisian patients with rheumatoid arthritis (RA).

Ninety RA patients with positive anti‐cyclic citrullinated antibodies (anti‐CCP) and 90 healthy blood donors (HBD) were studied. aCL and aβ2GPI of isotype IgG, IgA and IgM were detected by ELISA.

The frequency of antiphopholipid antibodies (aPL) (aCL and/or aβ2GPI) was significantly higher in patients with RA than in HBD (35.5% vs 11.1%, P = .0001). The frequencies of aCL and aβ2GPI were significantly higher in patients than in healthy subjects (15.5% vs 5.5%, P = .04 and 32.2% vs 11.1%, P = .0005 respectively). aβ2GPI‐IgA were significantly more frequent in patients than in the control group (26.7% vs 7.8%, P = .0007). In patients, aβ2GPI‐IgA were significantly more frequent than aβ2GPI‐IgG (26.7% vs. 6.7%, P = .0003) and aβ2GPI‐IgM (26.7% vs 5.6%, P = .0001). In RA patients, the frequency of aβ2GPI was significantly higher than that of aCL (32.2% vs 15.5%, P = .008). aβ2GPI‐IgA was significantly more frequent than aCL‐IgA (26.7% vs 4.4%, P = .00005). The average titer of anti‐CCP in aPL positive patients was significantly higher than in aPL negative patients (170.6 ± 50 RU/mL vs 147.7 ± 51 RU/mL, P = .04). Significant correlation was found between aβ2GPI‐IgA and anti‐CCP (r = .235, P = .026).

aPL and particularly aβ2GPI‐IgA are frequent in RA and are correlated with anti‐CCP.

• Tunisia
• anti-cardiolipin antibodies
• anti-β2 glycoprotein I antibodies
• rheumatoid arthritis

• Anti-β2GPI
• Autoimmunity
• Rheumatological disorder
• Thrombosis

• Autoimmune
• Gluten
• Prothrombin
• Thrombosis

Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed against membrane phospholipids in complex with phospholipid-binding proteins. Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis. This review focuses on the part played by anti-B2GPI in the pathogenesis of APS, their associations with different clinical phenotypes of the disorder and new avenues for refining the diagnostic potential of anti-B2GPI testing.

• antiphospholipid antibody
• antiphospholipid syndrome
• beta-2 glycoprotein I
• domain specific antibodies
• isotypes

• Tunisia
• anti Saccharomyces cerevisiae antibodies
• anti-β2 glycoprotein I antibodies

• Anti-cardiolipin antibodies
• Anti-phosphatidylserine/prothrombin
• Anti-β2-Glycoprotein-I antibodies
• Antiphospholipid antibodies
• Crohn’s disease
• Disease progression
• Thrombosis
• Ulcerative colitis

• Adult
• Antibodies, Antiphospholipid/blood
• Biomarkers/blood
• Colitis, Ulcerative/blood
• Colitis, Ulcerative/diagnosis
• Colitis, Ulcerative/epidemiology
• Colitis, Ulcerative/immunology
• Crohn Disease/blood
• Crohn Disease/diagnosis
• Crohn Disease/epidemiology
• Crohn Disease/immunology
• Crohn Disease/therapy
• Disease Progression
• Female
• Humans
• Hungary/epidemiology
• Male
• Middle Aged
• Phenotype
• Predictive Value of Tests
• Prevalence
• Prospective Studies
• Risk Factors
• Seroepidemiologic Studies
• Serologic Tests
• Tertiary Care Centers
• Young Adult

• Tunisia
• anti-beta 2 glycoprotein I antibodies
• anticardiolipin antibodies
• antiphospholipid antibodies
• primary biliary cirrhosis

Seronegative antiphospholipid syndrome (SNAPS) is an autoimmune disease present in patients with clinical manifestations highly suggestive of Antiphospholipid Syndrome (APS) but with persistently negative consensus antiphospholipid antibodies (a-PL). IgA anti-β2 Glycoprotein I (aB2-GPI) antibodies are associated with APS. However, they are not currently considered to be laboratory criteria due to the heterogeneity of published works and the use of poor standardized diagnostic systems. We have aimed to assess aPL antibodies in a group of patients with clinical manifestations of APS (C-APS) to evaluate the importance of the presence of IgA aB2GPI antibodies in APS and its relation with other aPL antibodies. Only 14% of patients with C-APS were positive for any consensus antibody, whereas the presence of isolated IgA aB2GPI antibodies was found in 22% of C-APS patients. In patients with arterial thrombosis IgA aB2GPI, antibodies were the only aPL antibodies present. Serologic profile in primary APS (PAPS) is different from systemic autoimmune disorders associated APS (SAD-APS). IgA aB2GPI antibodies are more prevalent in PAPS and IgG aB2GPI antibodies are predominant in SAD-APS. The analysis of IgA aB2GPI antibodies in patients with clinical manifestations of PAPS might avoid underdiagnosed patients and provide a better diagnosis in patients with SAD-APS. Laboratory consensus criteria might consider including analysis of IgA aB2GPI for APS diagnosis.

• Celiac disease
• Intracardiac thrombus
• Maladie cœliaque
• Myxoma
• Myxome
• Thrombophilia
• Thrombophilie
• Thrombus intracardiaque